Many with Psoriatic Arthritis Fail to Achieve Minimal Disease Activity Save

Despite the availability of numerous advanced therapies for psoriatic arthritis (PsA), there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study.

An observational, retrospective analysis of patient data from the Rhumadata™ and the International Psoriasis and Arthritis Research Team (IPART) registries, examined patient outcomes and the use of advanced therapy in PsA between January 2010 and December 2019. The primary endpoint was the percentage of patients failing to achieve minimal disease activity (MDA) within 6 months.

From a total of 1,596 adult PsA patients the percentage not achieving MDA within 6 months (with advanced therapy) was:

• 64.8% in Ontario
• 68.3% in Western Canada
• 74.8% in Québec 
• 75.0% in the Atlantic/East region

Failure to achieve MDA was higher amongst those treated with IL-17i compared with a TNFi in all regions (except Atlantic/East). Between 73.2 to 78.6% of patients reported pain at 6 months, and continuing functional impairment varied from 24.0% in the West to 83.3% in the Atlantic/East.

A higher thank expected number of incomplete outcomes (MDA) and wide regional variation in other outcomes that requires further study and better use of existing therapies.